Harvard University licenses its nasal swab collection technology, developed at the Wyss Institute and Harvard Medical School, to Mass startup Rhinostics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MCED is an emerging set of technologies that, when added to existing single cancer screening, provides an opportunity to identify a broad range of cancers earlier in the course of disease. With the use of a simple blood draw, urine, saliva, or stool sample test, MCED technology enables clinicians to rapidly screen for multiple types of cancer at once, potentially catching and treating them earlier. Multi-cancer early detection represents a paradigm shift in how cancers will be diagnosed and treated in the future, said Brian Druker, MD, director of the Knight Cancer Institute at Oregon Health & Science University, and a founding member of the MCED forum. By bringing together this group of experts from across the cancer research, clinical, and patient advocacy landscapes, we intend to evaluate evidence and establish standards for the emerging field of MCED that can guide physicians in adopting the technology in clinical practice. Ultimately, we are united in our mission to evaluate
th Annual Oncology Nursing Society (ONS) Congress. The virtual conference takes place on April 20, 22, 27 and 29, 2021. The nurse-led studies highlight the intersection of clinical knowledge, research, direct patient care and advocacy resulting in innovation. The ONS Congress is the largest, most comprehensive oncology nursing conference in the country.
The presentations focus on the effects of the COVID-19 crisis, the need for diversity, equity and inclusion in oncology nursing as well as the critical role oncology nurse navigators play in a patient’s treatment plan.
Notable presentations by Dana-Farber nurse/researchers include:
Primary Author: Renee Abdella, BSN, RN, OCN, BMTCN
Authors: Kathleen Spinello, DNP, RN, NE-BC; Rebecca Spitz, BSN, RN, OCN; Kimberly Mello, BSN, RN; Julie McCarthy, BSN, RN, PCCN; Jill Popp, BSN, RN, PCCN
BOSTON – Make-A-Wish
® Massachusetts and Rhode Island announced Dana-Farber Cancer Institute is the recipient of the 2021 Community Hero Award. Dana-Farber Cancer Institute President and Chief Executive Officer Laurie H. Glimcher, MD, received the award on April 10, 2021, at the Make-A-Wish
® Gala: Heroes for Hope, a live virtual event.
The Community Hero Award recognizes an organization or individual providing vital partnership in the Make-A-Wish Massachusetts and Rhode Island mission creating life-changing wishes for children with critical illnesses. Dana-Farber Cancer Institute has championed the Make-A-Wish mission for more than 30 years, referring more than 2,500 children in Massachusetts and Rhode Island to experience the powerful impact of a wish fulfilled.
Session Time: April 13, 11:17-11:39 a.m. EST
Summary: Kaelin will highlight the important physiologic constraints a cancer tissue must operate within, focusing on the critical role hypoxia plays in not only tumor growth but progression, and how modulating the hypoxia machinery will limit tumor progression. The ability to target cancer at several molecular levels provides hope that our therapies will not only be more effective but also more durable. The lingering question is how to deploy these approaches by identifying which patients are most likely to benefit.
In addition to the exciting research presentations, Andrew Aguirre, MD, PhD, of the Dana-Farber Center for Gastrointestinal Oncology, has been named a 2021 AACR NextGen Star. Aguirre will present during the NextGen Stars Spotlight Session: Genetics and Epigenetics.